newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and